Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.57
+0.01 (0.08%)
Mar 31, 2025, 1:26 PM EDT - Market open
Coya Therapeutics Employees
Coya Therapeutics had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$444,258
Profits / Employee
-$1,860,098
Market Cap
109.80M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8 | 0 | - |
Dec 31, 2023 | 8 | 2 | 33.33% |
Dec 31, 2022 | 6 | 0 | - |
Dec 31, 2021 | 6 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
COYA News
- 5 days ago - Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Business Wire
- 13 days ago - Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire
- 4 weeks ago - Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer's Disease Using GLP-1 Agonists and Combinations - Business Wire
- 7 weeks ago - Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD - Seeking Alpha
- 7 weeks ago - Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha
- 7 weeks ago - Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing - Benzinga
- 7 weeks ago - Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development - Business Wire
- 7 weeks ago - Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire